No Data
No Data
*ST Eye Medicine (600671.SH): Number of shareholders as of January 31, 2024 is 6,659
Gelonghui, Feb. 2丨*ST Eye Medicine (600671.SH) said on an interactive platform that as of January 31, 2024, the number of shareholders was 6,659.
*ST Eye Medicine (600671.SH): Expected net loss of 32.245,500 yuan to 40.245,500 yuan in 2023
Gelonghui announced on January 29丨*ST Eye Medicine (600671.SH) announced that it is expected to achieve net profit attributable to shareholders of listed companies of -40.245,500 yuan to -32.2455 million yuan in 2023. Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses for the year 2023 is estimated to be 41.134 million yuan to -33.1340 million yuan. According to preliminary estimates by the company's finance department, the company's annual revenue in 2023 is estimated to be RMB 116 million to RMB 126.0 million; it is estimated that the company's 2023 annual deductions and main operations
*ST Eye Medicine (600671.SH): Shareholder Yuanjia Medical voluntarily promises not to reduce the company's shares within 18 months
Gelonghui (600671.SH) announced on November 1, *ST Pharmaceutical () announced that, based on confidence in Tianmu Pharmaceutical's future development prospects and recognition of long-term investment value, Yuanjia Medical, a shareholder holding 12.36% of the company, made a voluntary commitment not to transfer its Tianmu Pharmaceutical shares within the next 18 months from November 1, 2023 (November 1, 2023 to April 30, 2025), including shares added during the commitment period due to capital reserves, distribution of stock dividends, allocations, and additional issuance of shares.
[Instant Analysis of BT Financial Report] *ST Meyao 2023 Interim Report: Debt Ratio Rises, Net Assets Turned Negative, Performance Pressure Increased
*ST Pharmaceutical (stock code: 600671) is a company mainly engaged in pharmaceutical manufacturing, drug distribution, traditional Chinese medicine diagnosis and treatment, and health. Its products include amoxicillin clavulanate potassium tablets, dendrobium officinale health products, etc., and the sales area is mainly concentrated in East China and South China. However, judging from its 2023 interim report, the company is facing some financial pressure. First, judging from the balance ratio, *ST's balance ratio rose from 98.51% at the beginning of the period to 107.47% at the end of the period. This indicates that the company's debt pressure has increased, and its liabilities have exceeded total assets, which makes up the company's operations
*ST Eye Drug (600671.SH): New official seal and contract-specific seal introduced
*ST Eye Drug (600671.SH) issued an announcement. The company is seriously worn and worn due to frequent use of official seals and special contract seals,...
TianMuShan Pharma Elects Chairman
Hangzhou TianMuShan Pharmaceutical Enterprise (SHA:600671) elected Liu Jiayong as chairman during a meeting on Friday. The appointment came weeks after Li Feng resigned as chairman due to personal rea
No Data